D. E. Shaw & Co., Inc. Bluebird Bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.85 - $1.26 $479,479 - $710,757	-564,093 Reduced 82.8%	117,175 $114,000
Q1 2024 May 15, 2024	BUY	$0.91 - $1.75 $619,953 - $1.19 Million	681,268 New	681,268 $872,000
Q2 2023 Aug 14, 2023	BUY	$2.79 - $5.03 $91,958 - $165,788	32,960 New	32,960 $108,000
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $595,313 - $875,947	103,174 Added 209.78%	152,355 $1.05 Million
Q3 2022 Nov 14, 2022	SELL	$3.75 - $7.39 $2.35 Million - $4.62 Million	-625,785 Reduced 92.71%	49,181 $311,000
Q2 2022 Aug 15, 2022	BUY	$2.94 - $5.23 $449,123 - $798,950	152,763 Added 29.25%	674,966 $2.79 Million
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $2.04 Million - $5.3 Million	500,255 Added 2279.27%	522,203 $2.53 Million
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $5,797 - $10,552	647 Added 3.04%	21,948 $219,000
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $1.39 Million - $2.6 Million	-123,867 Reduced 85.33%	21,301 $407,000
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $719,989 - $1.47 Million	-43,399 Reduced 23.02%	145,168 $4.38 Million
Q4 2020 Feb 16, 2021	SELL	$27.5 - $37.92 $3.18 Million - $4.39 Million	-115,764 Reduced 38.04%	188,567 $8.16 Million
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $440,522 - $559,606	-12,791 Reduced 4.03%	304,331 $16.4 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $8.14 Million - $13.8 Million	300,159 Added 1769.49%	317,122 $19.4 Million
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $2.68 Million - $6.51 Million	-102,549 Reduced 85.81%	16,963 $780,000
Q4 2019 Feb 14, 2020	BUY	$46.96 - $61.67 $5.29 Million - $6.95 Million	112,722 Added 1660.12%	119,512 $10.5 Million
Q3 2019 Nov 14, 2019	BUY	$59.47 - $93.1 $117,631 - $184,151	1,978 Added 41.11%	6,790 $623,000
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $57,259 - $79,433	755 Added 18.61%	4,812 $612,000
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $299,696 - $472,921	-5,071 Reduced 55.55%	4,057 $402,000
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $250,407 - $331,086	2,818 Added 44.66%	9,128 $1.33 Million
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $11.2 Million - $16 Million	-105,760 Reduced 94.37%	6,310 $1.08 Million
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $1.95 Million - $3.13 Million	23,974 Added 27.21%	112,070 $20 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $5.09 Million - $8.05 Million	88,096	88,096 $12.1 Million

Others Institutions Holding BLUE

# of Institutions

151

Shares Held

63.4M

Call Options Held

264K

Put Options Held

428K

Black Rock Inc. New York, NY

15.4M
Shares

$5.4 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

10.5M
Shares

$3.67 Million
0.0% of portfolio
Geode Capital Management, LLC Boston, MA

4.68M
Shares

$1.64 Million
0.0% of portfolio
Pictet Asset Management Sa Geneva 73, V8

4.67M
Shares

$1.63 Million
0.02% of portfolio
State Street Corp Boston, MA

3.84M
Shares

$1.34 Million
0.0% of portfolio

View Full List

About bluebird bio, Inc.

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

More about BLUE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account